Edition:
United States

People: Lannett Company Inc (LCI.N)

LCI.N on New York Stock Exchange

5.36USD
7 Dec 2018
Change (% chg)

$-0.10 (-1.83%)
Prev Close
$5.46
Open
$5.47
Day's High
$5.66
Day's Low
$5.34
Volume
250,540
Avg. Vol
340,712
52-wk High
$30.35
52-wk Low
$3.34

Crew, Timothy 

Mr. Timothy C. Crew is the Chief Executive Officer, Director of the Company. Mr. Crew has more than 25 years of experience in the generic and branded pharmaceutical industries, most recently serving as Chief Executive Officer of Cipla North America, a global pharmaceutical company based in Mumbai, India, from 2013 to 2017. Previously, he worked for eight years at Teva Pharmaceuticals Industries Ltd. (“Teva”), where he served as Senior Vice President and Commercial Operating Officer of the North American Generics division, the world’s largest generic operation with multibillion dollars of annual sales. Before that, he was Teva’s Vice President, Alliances and Business Development. From 2001 to 2004, Mr. Crew was Executive Vice President, North America, for Dr. Reddy’s Laboratories Ltd. Mr. Crew began his pharmaceutical career at Bristol-Myers Squibb, where he held a number of senior management positions in global marketing, managed healthcare, marketing, business development and strategic planning. Prior to his pharmaceutical roles, Mr. Crew served in the United States Army, where he rose to the rank of Captain. Mr. Crew earned a Bachelor of Arts degree in economics from Pomona College and a Masters of Business Administration degree from Columbia Business School.

Basic Compensation

Total Annual Compensation, USD 350,539
Restricted Stock Awards, USD 400,016
Long-Term Incentive Plans, USD --
All Other, USD 579,226
Fiscal Year Total, USD 1,329,780

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Patrick LePore

129,785

Timothy Crew

1,329,780

Martin Galvan

763,745

John Abt

565,013

Maureen Cavanaugh

--

Grant Brock

--
As Of  29 Jun 2018